Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: A randomized controlled trial

Drug and Alcohol Dependence

Volumn 120, Issue 1-3, 2012, Pages 48-54

  DeFulio, Anthony ^a   Everly, Jeffrey J ^a   Leoutsakos, Jeannie Marie S ^a   Umbricht, Annie ^a   Fingerhood, Michael ^a   Bigelow, George E ^a   Silverman, Kenneth ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Contingency management; Extended release naltrexone; Heroin; Incentives; Opioid pharmacotherapy; Therapeutic workplace

Indexed keywords

COCAINE; NALTREXONE; OPIATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; EMPLOYMENT; EXTENDED RELEASE FORMULATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH BEHAVIOR; HUMAN; MALE; OPIATE ADDICTION; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; WORKPLACE;

ADULT; DELAYED-ACTION PREPARATIONS; EMPLOYMENT; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; REINFORCEMENT (PSYCHOLOGY); WORKPLACE;

EID: 84155164801     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.06.023     Document Type: Article

References (33)

1. Adi Y., Juarez-Garcia A., Wang D., Jowett S., Frew E., Day E., Bayliss S., Roberts T., Burls A. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol. Assess. 2007, 11:1-85.
2. American Psychiatric Association Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 2000, American Psychiatric Association, Washington, DC.
3. Avants S.K., Margolin A., Kosten T.R. Cocaine abuse in methadone maintenance programs: integrating pharmacotherapy with psychosocial interventions. J. Psychoactive Drugs 1994, 26:137-146.
4. Comer S.D., Collins E.D., Kleber H.D., Nuwayser E.S., Kerrigan J.H., Fischman M.W. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl.) 2002, 159:351-360.
5. Comer S.D., Sullivan M.A., Yu E., Rothenberg J.L., Kleber H.D., Kampman K., Dackis C., O'Brien C.P. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2006, 63:210-218.
6. Comer S.D., Sullivan M.A., Hulse G.K. Sustained-release naltrexone: novel treatment for opioid dependence. Expert Opin. Invest. Drugs 2007, 16:1285-1294.
7. Compton W.M., Cottler L.B., Dorsey K.B., Spitznagel E.L., Mager D.E. Comparing assessments of DSM-IV substance dependence disorders using CIDI-SAM and SCAN. Drug Alcohol Depend. 1996, 41:179-187.
8. DeFulio A., Donlin W.D., Wong C.J., Silverman K. Employment-based abstinence reinforcement as a maintenance intervention for the treatment of cocaine dependence: a randomized controlled trial. Addiction 2009, 104:1530-1538.
9. Donlin W.D., Knealing T.W., Needham M., Wong C.J., Silverman K. Attendance rates in a workplace predict subsequent outcome of employment-based reinforcement of cocaine abstinence in methadone patients. J. Appl. Behav. Anal. 2008, 41:499-516.
10. Everly J.J., DeFulio A., Koffarnus M.N., Leoutsakos M.S., Donlin W.D., Aklin W.M., Umbricht A., Fingerhood M., Bigelow G.E., Silverman K. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Addiction 2011, 106:1309-1318.
11. Galai N., Safaeian M., Vlahov D., Bolotin A., Celentano D.D. ALIVE Study. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort, 1988-2000: description and determinants. Am. J. Epidemiol. 2003, 158:695-704.
12. Hser Y.I., Hoffman V., Grella C.E., Anglin M.D. A 33-year follow-up of narcotics addicts. Arch. Gen. Psychiatry 2001, 58:503-508.
13. Kernan W.N., Viscoli C.M., Makuch R.W., Brass L.M., Horowitz R.I. Stratified randomization for clinical trials. J. Clin. Epidemiol. 1999, 52:19-26.
14. Krupitsky E., Nunes E.V., Ling W., Illeperuma A., Gastfriend D.R., Silverman B.L. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011, 1506-1513.
15. Martin W.R., Jasinski D.R., Mansky P.A. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch. Gen. Psychiatry 1973, 28:784-791.
16. McLellan A.T., Lewis D.C., O'Brien C.P., Kleber H.D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000, 284:1689-1695.
17. McLellan A.T., Luborsky L., Cacciola J., Griffith J., Evans F., Barr H.L., O'Brien C.P. New data from the Addiction Severity Index. Reliability and validity in three centers. J. Nerv. Ment. Dis. 1985, 173:412-423.
18. Mello N.K., Mendelson J.H., Kuehnle J.C., Sellers M.S. Operant analysis of human heroin self-administration and the effects of naltrexone. J. Pharmacol. Exp. Ther. 1981, 216:45-54.
19. Modesto-Lowe V., Van Kirk J. Clinical uses of naltrexone: a review of the evidence. Exp. Clin. Psychopharmacol. 2002, 10:213-227.
20. Preston K.L., Silverman K., Umbricht A., DeJesus A., Montoya I.D., Schuster C.R. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 1999, 54:127-135.
21. Robles E., Stitzer M.L., Strain E.C., Bigelow G.E., Silverman K. Voucher-based reinforcement of opiate abstinence during methadone detoxification. Drug Alcohol Depend. 2002, 65:179-189.
22. Schuh K.J., Walsh S.L., Stitzer M.L. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology (Berl.) 1999, 145:162-174.
23. Silverman K., Bigelow G.E., Stitzer M.L. Treatment of cocaine abuse in methadone maintenance patients. Cocaine Abuse 1998, 363-388. Academic Press, San Diego. S.T. Higgins, J.L. Katz (Eds.).
24. Silverman K., Robles E., Mudric T., Bigelow G.E., Stitzer M.L. A randomized trial of long-term reinforcement of cocaine abstinence in methadone maintained patients who inject drugs. J. Consult. Clin. Psychol. 2004, 72:839-854.
25. Silverman K., Svikis D., Robles E., Stitzer M.L., Bigelow G.E. A reinforcement-based therapeutic workplace for the treatment of drug abuse: six-month abstinence outcomes. Exp. Clin. Psychopharmacol. 2001, 9:14-23.
26. Silverman K., Svikis D., Wong C.J., Hampton J., Stitzer M.L., Bigelow G.E. A reinforcement-based therapeutic workplace for the treatment of drug abuse: three-year abstinence outcomes. Exp. Clin. Psychopharmacol. 2002, 10:228-240.
27. Silverman K., Wong C.J., Needham M., Diemer K.N., Knealing T., Crone-Todd D., Fingerhood M., Nuzzo P., Kolodner K. A randomized trial of employment-based reinforcement of cocaine abstinence in injection drug users. J. Appl. Behav. Anal. 2007, 40:387-410.
28. Singer J.D. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J. Educ. Behav. Stat. 1998, 24:323-355.
29. Sullivan M.A., Garawi F., Bisaga A., Comer S.D., Carpenter K., Raby W.N., Anen S.J., Brooks A.C., Jiang H., Akerele E., Nunes E.V. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend. 2007, 91:289-292.
30. United States Department of Transportation, Office of Drug and Alcohol Policy and Compliance, 49 CFR Part 40 (Drug and Alcohol Regulation), Washington, DC. Available: (accessed May 2011). http://www.dot.gov/ost/dapc/NEW_DOCS/PART40.pdf.
31. Walsh S.L., Sullivan J.T., Preston K.L., Garner J.E., Bigelow G.E. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J. Pharmacol. Exp. Ther. 1996, 279:524-538.
32. Wilkinson G.S. WRAT-3: Wide Range Achievement Test Administration Manual 1993, Wide Range, Inc., Wilmington, DE.
33. Zeger S.L., Liang K.Y., Albert P.S. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988, 44:1049-1060.